Targeted drug combo for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has come back or spread to other parts of the body.
- You have already had at least one type of chemotherapy with platinum, which no longer works or you can't take it.
- Your tumor must have a specific protein called HER2 on its surface (tested in a central lab).
- You are at least 18 years old, able to do daily activities with little to no help (ECOG 0 or 1), and expected to live at least 12 weeks.
- Your main organs (like blood cells, kidneys, liver, and heart) must be working well enough to handle the treatment.
- You cannot have cancer that has spread to your brain, active infections, or other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
This study tests a combination of two drugs—utidelone (a chemotherapy-like drug that targets cell division) and toripalimab (an immunotherapy that helps your immune system attack cancer). It is for people with advanced cervical cancer that has not gone away or has spread, and who have already tried standard chemotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
This trial tests a combination of two drugs for cervical cancer that has returned or spread after initial treatment. The drugs target cancer cells with a specific marker called HER2 and may help shrink tumors or slow their growth.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.